Selecting the Right RORγt Agonist: Implications for Cancer Immunotherapy

Marcin Ratajewski

PDF(2115 KB)
For Authors|For Editors|For Reviewers
PDF(2115 KB)
Discovery Medicine ›› 2025, Vol. 37 ›› Issue (199) : 1713-1717. DOI: 10.24976/Discov.Med.202537199.148
Editorial

Selecting the Right RORγt Agonist: Implications for Cancer Immunotherapy

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 37(199): 1713-1717 https://doi.org/10.24976/Discov.Med.202537199.148

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(2115 KB)

Accesses

Citation

Detail
Sections
Recommended
Follow Us on
Copyright © 2025.
By using this website, you agree to our Terms & Conditions and Privacy Policy.  
  • Disclaimer
    The statements, opinions and data contained in Discovery Medicine are solely those of the individual authors and contributors and not of the journal and the editor(s). Discovery Medicine stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    • /

    〈 〉